SCHEMBL2280683

SCHEMBL2280683

COCCNC(=O)c1cccc(/C=C/C(=O)c2c(O)cc(C)[nH]c2=O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.43
HTT P42858 4/20 0.43
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
NPSR1 Q6W5P4 2/20 0.43
P4HB P07237 4/20 0.42
CYP2C19 P33261 2/20 0.41
HPGD P15428 2/20 0.41
CYP1A2 P05177 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CYP19A1 P11511 1/20 0.39
CYP2C9 P11712 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2280689 1.00 LMNA (0.43) LMNAHTTMAPTSMN1; SMN2NPSR1
SCHEMBL2274875 0.89 LMNA (0.50) LMNAHTTMAPTSMN1; SMN2NPSR1
SCHEMBL2274871 0.89 LMNA (0.50) LMNAHTTMAPTSMN1; SMN2NPSR1
SCHEMBL2275109 0.89 LMNA (0.43) LMNAHTTMAPTSMN1; SMN2NPSR1
SCHEMBL2275114 0.89 LMNA (0.43) LMNAHTTMAPTSMN1; SMN2NPSR1
SCHEMBL2279543 0.86 LMNA (0.47) LMNAHTTMAPTSMN1; SMN2NPSR1
SCHEMBL2279537 0.86 LMNA (0.47) LMNAHTTMAPTSMN1; SMN2NPSR1
SCHEMBL2284238 0.86 LMNA (0.41) LMNAHTTMAPTSMN1; SMN2NPSR1
SCHEMBL2284323 0.85 LMNA (0.43) LMNAHTTMAPTSMN1; SMN2NPSR1
SCHEMBL2284334 0.85 LMNA (0.43) LMNAHTTMAPTSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 LMNA 537/4885HTT 4798/4885MAPT 4848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.